Changing the
   Rules of

 Biopharma

    Discovery

Changing the Rules of Biopharma Discovery


Changing the Rules
      of Biopharma
                 Discovery


About Us

About Us

Medera strives to eradicate difficult-to-treat and incurable cardiovascular diseases using gene and cell therapies, human mini-organs and other state-of-the-art technologies pioneered by our portfolio companies and partners

Cardiovascular disease research

Our Companies

Founded in 2014, Novoheart has the longest history in commercializing human cardiac tissue engineering for disease modeling and drug screening. Our founders were among the first-generation biomedical engineers who started the fields back in the late 90s. Novoheart has the industry’s most sophisticated and comprehensive human cardiac tissue engineering platform and the only Human-Heart-in-a-Jar.

Novoheart was previously dually publicly-listed on the Toronto Stock Exchange and Frankfurt Stock Exchange before its acquisition and privatisation by the Medera group in 2020.

Click to Visit the Novoheart Site Click to Visit the Novoheart Site

Founded in 2019 by the scientific pioneers who started the fields of Cardiac Gene Therapy over three decades ago at the Massachusetts General Hospital of Harvard University, Sardocor is a fully owned subsidiary of the Medera Group.

Sardocor is dedicated to the clinical development of novel therapies for patients with incurable diseases. With three ongoing gene therapy clinical trials for Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF) and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), Sardocor is currently second to none in terms of the number of FDA Investigational New Drug (IND) approvals and the clinical stage maturity.

Click to Visit the Sardocor Site Click to Visit the Sardocor Site

Management Team

Management Team

Ronald Li

Ronald Li

Chairman and Chief Executive Officer

Roger Hajjar

Roger Hajjar

President and Chief

Medical Officer 

Kevin Costa

Kevin Costa

Chief Science Officer

Shiva Singh

Shiva Singh

Chief Corporate Development Officer

Share by: